GSK Overview - Global

of one

GSK Overview - Global

GSK has several social and medical initiatives for under served populations including Smiles For Kinds, Comic Relief, and Save The Children. They invested $4.95 billion in R&D last year and had $39.83 billion in revenue. They are heavily focused on cancer curing technologies and vaccine development.


  • GSK's values are Patient Focus, Transparency, Respect, and Integrity. Their expectations are Courage, Accountability, Development, and Teamwork.
  • They have 46 new medicines in development, 33 are targeting the immune system.
  • They are state their current purpose is to develop new medical innovations, vaccines, consumer healthcare products, improve global health, improve R&D for infectious diseases, and focusing on HIV & TB health, tackling antimicrobial resistance and preparing for pandemic outbreaks is also a priority concern.
  • There are "17 immuno-0ncology assets in clinical development".
  • In 2018, they invested $4.95 billion in R&D.
  • According to Hoovers, they have 99,817 employees, $74 billion in assets, a net income growth of 124%, and $39.83 billion in revenue for 2018.


  • The pharmaceutical market is extremely competitive. Johnston & Johnston, Roche, Pfizer, Novartis, Merk, Sanofi, Bayer, Amgen, Gilead, and Sinopharm Group are all considered competitors in this market. Their revenue for 2017 is as follows: (GSK's 2017 revenue was $40.7 billion)
  • Johnson & Johnson- $62.9 billion
  • Pfizer- $52 billion
  • Novartis- $49 billion
  • Sinbopharm Group- $42.6 billion
  • Roche- $42.2 billion
  • Sanofi- $40.66 billion
  • Merk- $40.1 billion
  • Bayer- $29.1 billion
  • Gilead- $26.1 billion


  • Nucala is a treatment for asthma. They are currently investigating its usefulness in treating COPD. This has been prescribed to over 30,000 patients in the US. Recently two new self-administration methods were approved so the drug may now be taken at home if deemed appropriate.
  • Trelegy Ellipta is an inhaled medication to treat COPD. It is used once a day. It contains "fluticasone furoate, an inhaled corticosteroid, umeclidinium, a long-acting muscarinic antagonist; and vilanterol, a long-acting beta2-adrenergic agonist, delivered in GSK’s Ellipta dry powder inhaler, which is used across the entire new portfolio of inhaled COPD medicines". It has met the goals of a late stage study. A phase three study was recently completed on its treatment of uncontrolled asthma. It showed significant improvement and improved lung function.
  • Anoro Ellipta is a combination of two bronchodilators in a dry powder inhaler.
  • Breo Ellipta is a once daily treatment for adult asthma patients that is long acting.
  • GSK is working a potentially new class of immunothereaphy drugs to treat common cancers. The research is focused around a protein called STING. It can release T-cells into the body to fight off cancer. They are working on a way to activate this protein, and have has some promising results. These molecules could be injected into the bloodstream instead of the tumor. In 2019, they will be progressing to human safety studies. They also see potential for turning this protein off and becoming a treatment for autoimmune diseases like Lupus.
  • GSKL is continuing their COPD research and has identified several biomarkers that can be used in trials.
  • Tuberculosis (TB) is a top ten cause of death. GSK is closer to finding a new vaccine. GSK has been working for years with Aeras, a non-profit biotech company to develop this. It is in clinical trials (phase 2) and has been tested on high risk areas in Africa. This vaccine can possibly prevent individuals with latent TB from getting pulmonary TB. Results will be available later this year.
  • GSK is using "Self Amplifying Messenger RNA (SAM), Adjuvants, Bioconjugates, GMMA (Generalized Modules for Membrane Antigens) and Chad (Chimpanzee adenovirus)" technologies to develop new vaccines. They take part of the RNA code of a virus and make messenger RNA molecules. Once injected into a patient, the cells begin to produce the vaccine. Adjuvant technology enables them to make vaccines that target certain age groups.
  • Dovato, a new HIV treatment approach made up of two drugs, was approved by the FDA this year. It is a single tablet medicine that is made up of dolutegravir and lamivudine. This drug has been shown to have the same efficacy as older drugs with less toxicity.
  • Zejula from Tesaro has been submitted to the FDA as a possible treatment for advanced "ovarian, fallopian tube, or primary peritoneal cancer patients who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with either the BRCA mutation or Homologous recombination deficiency (HRD) and have progressed more than six months after the last platinum-based chemotherapy." A decision will be made by October 24, 2019.
  • Shingrix has been approved to treat shingles in China for patients over 50. This medicine was on a list that China has accepted for expedited approval. It has shown over 90% efficacy rate. It will be available in 2020.
  • If approved, ViiV Healthcare's (a part of GSK) new treatment for HIV will be the first ever once-monthly, injectible medication for HIV. It has proven as effective as the oral combination medications in testing on patients with a suppressed viral load. This regime consists of the drugs cabotegravir and rilpivirine.


  • Voltaren is a GSK brand that centers around inclusive design. Voltaren is used for osteoarthritis. They have redesigned the package to be easier to hold and open. They have also redesigned Panadol packaging so parents can deliver medicine with one hand.


  • GSK has a goal of using technology to make sure they are there when the patient needs them. Seventy-five percent of consumers research medications online. GSK is working with retailers and consumers to come up with digital solutions.
  • GSK developed a flu tracker in conjunction with their drug Theraflu for the Russian market. It used social information and weather data to identify at risk areas. The app then informed the users and recommended solutions. It was more successful than their attempts to do the same thing on their website.
  • GSK partnered with Google to work on in house data management, GSK became the first healthcare company to own their own full tech stack.
  • GSK has a digital innovation hub that is global for their business along with an advisory board.
  • They have set priorities to upgrade media and change up the media mix/marketing.
  • Responsible Health Initiatives a partnership between GSK, Teva, EcoVadis, and Takeda. Their goal is to use technology to improve the global healthy supply chain. Their vision includes improving standards for CSR assessments, adopting a common platform for CSR performance, implementing shared tools, and working together to reduce risk in the supply chain.


  • Goals have been set to reach 800 million undeserved people in developing countries by 2025 with their products and to provide 12 million people with healthcare access.
  • They strive to be a modern employer that focuses on engaged people, inclusion, diversity, health and well-being.
  • GSK operates the Tres Cantos lab that allows international scientists to pursue their own projects. Researchers are able to access GSK's expertise in this collaborative approach to drug discovery.
  • The AMR Industry Alliance is a partnership to provide access to antibiotics and vaccines. The goals of this initiative are to ensure the access to these medications is affordable. They have agreed to cap the price of needed medicines at 25% of the cost to a developed country. They want to protect 300 million children by 2024.


  • GSK is in a partnership with the University of California. They are establishing a state-of-the-art laboratory for CRISPR (DNA) technologies to study genomic research. They will be working on gene mutations and how they can cause disease. CRISPR allows them to do this on a larger scale than ever thought possible. GSK will spend up to $67 million on this project over the next five years.
  • GSK has partnered with Pfizer to create a Consumer Healthcare Joint Venture on December 19, 2018.
  • Medicine for Malaria is another GSK initiative to fight one of the oldest diseases known to man. They share there Tres Cantos research facility with other researchers in the malaria community. They have developed a dingle dose "tafenoquine" that has been approved in Australia and the US. It is the first new treatment in 60 years. They will be bringing 10 million doses of RTS, a vaccine, to children in Africa.
  • Comic Relief, a UK charity, has partnered with GSK to create an almost $28 million dollar fund to fight malaria. They are supporting 22 community projects in Africa and Asia. So far, they have reached 1.7 million people.
  • A partnership with 23andMe that will last four years has been announced recently. They will collaborate in the area of genetic and phenotypic research with a goal of developing new medicines for unmet medical needs. They have set goals to improve target selection groups, identify subgroups that are most likely to respond to treatment, and to find more effective ways to recruit for clinical studies.
  • GSW works with Save the Children to prevent child deaths from preventable/treatable diseases. They have goals to improve access to healthcare, training workers in the poorest communities, developing child-friendly medication, and "working for stronger child health policies". They have reached over 2.8 million children.
  • Smile Train has partnered with GSK to treat cleft-palate and other orthodontic issues. GSK will provide them with funding.


To select the competitors to GSK we located multiple top lists and SWOT analysis where competitors where listed. They are shared in the sources. After locating the revenue of each pharmaceutical company, we ordered them by revenue.

Please note that there are multiple instances where we used quotes to not detract from the scientific jargon.

  • "The drug maker GlaxoSmithKline announced Thursday that it would team up with some of the nation’s most prominent CRISPR researchers to use the gene-editing technology in a search for new medicines, establishing a new lab in San Francisco and spending up to $67 million over five years."
  • "GlaxoSmithKline plc today announced a five-year collaboration with the University of California to establish a state-of-the-art laboratory for CRISPR technologies, the Laboratory for Genomics Research (LGR). The new laboratory will explore how gene mutations cause disease and develop new technologies using CRISPR to rapidly accelerate the discovery of new medicines."
  • "With the recent explosion of information from human genetics, scientists need powerful tools to understand why small changes in a person’s genetic make-up can increase the risk of diseases, an area of science called functional genomics. The most powerful tool in functional genomics, CRISPR, allows this to be done at a scale once thought impossible. Through this research, scientists can discover and develop novel therapies that have a higher likelihood of becoming medicines [1]."
  • "The LGR represents a novel hybrid model that brings together industrial and academic researchers under a single roof working on projects both together and independently. The outputs of those research projects will be focused on technologies, new drug targets and biological mechanisms that will foster both academic and industrial advances."
  • "We have 3 global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. Our goal is to be one of the world’s most innovative, best performing and trusted healthcare companies."
  • "Our values are Patient focus, Transparency, Respect, Integrity. Our expectations are Courage, Accountability, Development, Teamwork. "
  • "33 of the 46 new medicines now in development targeting modulation of the immune system "
  • "17 immuno-oncology assets now in clinical development "
  • "• £3.9bn ($4.96b) R&D investment in 2018 "
  • "Strengthening our pipeline remains our number one priority and we reported positive data for several potential new medicines in HIV and Oncology during the quarter"
  • "GSK is also presenting several abstracts providing additional clinical evidence for GSK’s anti-IL 5 monoclonal antibody, Nucala (mepolizumab), in severe eosinophilic asthma (SEA) and eosinophilic granulomatosis with polyangiitis (EGPA). Additionally, data will be presented for an investigative use, chronic obstructive pulmonary disease (COPD), where GSK will be initiating a phase III trial in the second half of 2019."
  • "About Trelegy Ellipta (FF/UMEC/VI) FF/UMEC/VI is the first COPD treatment to provide a combination of three molecules in a single inhaler that only needs to be taken in a single inhalation, once a day. It contains fluticasone furoate, an inhaled corticosteroid, umeclidinium, a long-acting muscarinic antagonist; and vilanterol, a long-acting beta2-adrenergic agonist, delivered in GSK’s Ellipta dry powder inhaler, which is used across the entire new portfolio of inhaled COPD medicines. Data from across multiple clinical programmes have demonstrated the benefit of the molecules in FF/UMEC/VI both alone and in combination, for the treatment of COPD."
  • "About Nucala (mepolizumab) Nucala 100mg is the market leading biologic treatment for patients with severe eosinophilic asthma. It is approved in the US, Europe and over 20 other markets and has been prescribed to over 30,000 patients in the US. It has been studied in over 3,000 patients in 16 clinical trials across a number of eosinophilic conditions."
  • "In the US, Nucala (100mg fixed dose subcutaneous injection of mepolizumab) is licensed as an add-on maintenance treatment for patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. Nucala (3x 100mg subcutaneous injection of mepolizumab) is licensed for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). Nucala is not approved for the relief of acute bronchospasm or status asthmaticus. Full US Prescribing Information is available at US Prescribing Information Nucala."
  • "About Anoro Ellipta Anoro Ellipta (umeclidinium and vilanterol inhalation powder) is a combination of two bronchodilators in GSK’s Ellipta dry powder inhaler. It contains umeclidinium (UMEC), a long-acting muscarinic antagonist (LAMA) and vilanterol (VI), a long-acting beta2 agonist (LABA). The dose of UMEC/VI is labelled as 55/22mcg in Europe (delivered dose) and 62.5/25mcg in the US (dispensed dose) and is delivered in the Ellipta inhaler."
  • "About BREO ELLIPTA In the US BREO ELLIPTA is indicated for the once-daily treatment of asthma in patients aged 18 years and older uncontrolled on a long-term control medication (e.g. an inhaled corticosteroid (ICS)) or whose disease warrants an ICS and long-acting beta2-adrenergic agonist (LABA). "
  • "BREO 100/25 is indicated for the long-term, once-daily for maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema, and for reducing COPD exacerbations in patients with a history of exacerbations. BREO 100/25 is the only strength indicated for COPD."
  • "GlaxoSmithKline plc (LSE/NYSE: GSK) today has announced that the shareholder resolution relating to the transaction between GSK and Pfizer Inc to create a Consumer Healthcare Joint Venture, which was announced on 19 December 2018 was approved at a General Meeting held by GSK today. 99.85% of shareholders voted for the resolution. "
  • "Our purpose is to help people do more, feel better, live longer by using our science and technology to address health needs. "
  • "New medical innovations Develop differentiated high-quality and needed medicines, vaccines and consumer healthcare products to improve health Global health Improve global health impact through R&D for infectious diseases that affect children and young people in developing countries focusing on HIV, malaria and TB Health security Help the world to better prepare for future disease outbreaks with pandemic potential, and tackle antimicrobial resistance"
  • "By making our products affordable and available Pricing Improve the health of millions of people each year by making our products available at responsible prices that are sustainable for our business Product reach Use access strategies to reach 800 million underserved people in developing countries with our products by 2025 Healthcare access Partner to improve disease prevention, awareness and access to healthcare services for 12 million people by 2025"
  • "By being a modern employer - Engaged People - Inclusion and Diversity - Health, wellbeing and development "
  • "Being a responsible business Reliable supply Commit to quality, safety and reliable supply of our products for patients and consumers Ethics and values Operate an ethical, values-driven culture, in which any issues are responded to swiftly and transparently Data and engagement Use data responsibly and transparently. Improve patient and scientific engagement Environment Reduce our environmental impact by one quarter by 2030"
  • "Our Voltaren brand is a clear example of inclusive design in action. Voltaren is a product used by people who have dexterity issues or who could suffer with osteoarthritis. Taking that into consideration, it was critical that the packaging design would be easy to hold and open for people with this reduced ability."
  • "“We also know that our capabilities or our exclusions from products and services may change over time,” said Andrew. “Some will be permanent or persistent, they will always be there – perhaps being deaf or blind from birth. Others will be temporary for example we might break our arm, injure our backs, spend a week in a country where we don’t speak the language.”"
  • "We took this situational approach into consideration when designing a syringe for our Panadol children’s medication. We realised that many parents would be using this product with one hand while they held they children in the other. So, it was specifically designed to be used one-handed. It also has a comfortable mouth piece, controlled dispensing of medication to improve the experience for the child, and clear visible markings to help the parent or carer to dose accurately."
  • "Malaria is one of the world’s oldest diseases, with evidence of the mosquito-borne illness found in tissues from Ancient Egyptian mummies. *But despite its long history and our understanding of its biology, malaria remains one of the world’s deadliest diseases."
  • "The fight begins in our labs. At our research and development facility at Tres Cantos in Spain, we have scientists from inside and outside GSK working on malaria. These scientists, are carrying out innovative research focused on the very earliest stages of discovery. Our researchers share Tres Cantos facilities with researchers in the malaria community across the globe to give them a chance to determine their compound’s potential to kill the malaria parasite quickly."
  • "Developed in partnership with Medicine for Malaria Ventures, single-dose tafenoquine was approved for use in adults in the US and Australia. It is the first new treatment for prevention of relapse in P. vivax malaria in more than 60 years and marks a major contribution towards malaria eradication efforts. Building on this, since a significant part of the global burden of P. vivax malaria is in children, we are also studying the use of tafenoquine in young patients. "
  • "As part of our efforts, together with our partners, our intent is to provide tafenoquine at an affordable price in malaria endemic countries."
  • "But after more than 30 years of research, along with our partners, we are closer than ever to bringing a vaccine –RTS,S – to young children in Africa. Following one of the biggest trials of its kind in sub-Saharan Africa and the positive scientific opinion of the European Medicines Agency in 2015, the WHO called for a pilot implementation of the vaccine through routine immunization programme. This WHO-coordinated pilot implementation programme will take place in selected regions of Ghana, Malawi and Kenya, starting in 2019. "
  • "We are donating up to 10 million vaccine doses for the pilot implementation of the vaccine."
  • "Partnerships are also critical when it comes to strengthening health systems as it needs a combination of government, civil society and business working together. So we have teamed up with Comic Relief, the UK charity, with whom we’ve created a £22 million fund to fight malaria."
  • "Through the partnership, we are supporting 22 community projects with grants in sub-Saharan Africa and the Greater Mekong sub-region of south-east Asia. These projects range from youth-led approaches to training healthcare workers and volunteers – all with a view to helping people access prevention, diagnosis and treatment at the right time, in the right place. Together, we have so far reached more than 1.7 million people, including over 165,000 pregnant women and over 226,000 children under five."
  • "A paper authored by 44 of our scientists was published in the scientific journal Nature, revealing a potential new class of immunotherapy drugs to treat some of the most common cancers. We take a closer look at how these molecules work and what they might mean for the future of cancer treatment."
  • "One of the proteins that piqued our scientists’ interest is called STING. When active it triggers the body to release a sub set of T-cells that are capable of recognising and destroying cancer cells. But how do we activate it?"
  • "“Finding a molecule that is a match with the protein you’re looking for is a difficult process. We’ve been studying STING for a number of years to learn more about how it works and what it causes in the cell. Through screening multiple libraries of molecules, we found a family of molecules that showed promising activity, and by tweaking their properties, made them a more efficient activator of the STING protein,” commented Joshi Ramanjulu, Senior Director of Medicinal Chemistry and lead author on the study."
  • "“One of the potential advantages of these new molecules is they can be given by injection into the bloodstream as opposed to directly into a tumour, which can be tricky. They can potentially reach inaccessible solid tumours and clumps of cancer cells that have broken away from the main tumour, which could potentially expand the treatment options for patients. We also saw in mouse models of cancer that the new molecules activated the immune system ‘memory’ meaning that if the cancer was to come back then the immune cells were primed and ready to attack without needing more treatment.”"
  • "“We’ll keep studying STING activators as potential cancer treatments. The next step for us will be to move into human safety studies of the molecules, which we expect to start in 2019. The biology of STING is really interesting, so we are also exploring the effects of switching STING on as a way of boosting response to vaccines and how switching STING off could be a potential treatment route for some autoimmune diseases such as Lupus,” Joshi added."
  • "Several more studies have now been undertaken to understand this extrapulmonary (beyond the lungs) aspect of COPD and have given us great insight, enabling us to move forward with our research. For example, we’re now able to identify several important biomarkers that can be used in trials when we’re assessing medicines targeting the cardiovascular and muscle aspects of COPD."
  • "In data from ECLIPSE we recently described a group of participants with Multi-Organ Loss of Tissue or ‘MOLT’. These patients demonstrated accelerated worsening of emphysema (over inflation of the air sacs in the lung) but they also reported more bone loss (osteoporosis) and demonstrated more body and muscle mass loss over the three-year duration of the study. We also observed there were more deaths and events requiring hospitalisation in these patients."
  • "The study revealed participants in the MOLT group had a specific pattern of protein biomarkers (a molecular fingerprint) in their blood, which suggested these patients have a defect in their body’s ability to repair tissue. So, although current therapies can help them with their symptoms, we must still find a way to prevent their progressive decline. "
  • "Tuberculosis – better known as TB – is one of the top ten causes of deaths worldwide. But for the first time in almost 100 years, we have taken a major step towards finding a potential new vaccine against the disease."
  • "Around 20-30% of patients do not finish their treatment and this creates opportunities for deadlier, drug-resistant strains to develop. Combined with the lack of new treatment options in recent years, this has contributed to a surge of new cases of TB."
  • "Currently, there is only one TB vaccine available – the Bacillus Calmette–Guérin vaccine, better known as the BCG. Given to babies, the vaccine prevents severe disease in children but its effectiveness against pulmonary TB in adults varies. The BCG vaccine plays an essential role to protect babies in TB endemic countries, but it is not enough to control the disease at a global scale."
  • "Over the last 15 years, we have been working with Aeras, a not-for-profit biotech, to develop a TB candidate vaccine, with the support of the Bill & Melinda Gates Foundation, the UK’s Department for International Development and others. As Aeras’ TB vaccine clinical programme was recently acquired by IAVI, a longstanding GSK collaborator in HIV vaccine development, IAVI will now also be collaborating with us on our TB vaccine programme."
  • "Our candidate vaccine has been tested in a phase II clinical trial in TB-endemic regions of Africa. Primary results after a two-year follow-up of the study’s participants, published in the New England Journal of Medicine, showed the candidate vaccine could help prevent adults with latent TB infection from becoming sick with pulmonary TB. The study was completed at the end of 2018, and the final study results will be available later in 2019."
  • "The Tres Cantos Open Lab offers top international scientists and academics the opportunity to pursue their own projects as part of an integrated team."
  • "That idea, together with the angst that big pharma would want to claim rights to her research findings, had been Thulasi’s preconceptions before she began her secondment in our Open Lab at Tres Cantos in Spain in 2014. But within days of arriving from New York’s Weill Cornell Medical College, Thulasi realised that quite the reverse is true. The Open Lab does what it says on the tin."
  • "The Tres Cantos Open Lab offers top international scientists and academics the opportunity to pursue their own projects as part of an integrated team. Researchers are able to access GSK’s expertise, processes, and industrial-scale infrastructure as part of a collaborative approach to drug discovery."
  • "Adjuvants, SAM (Self Amplifying Messenger RNA), Bioconjugates, GMMA (Generalized Modules for Membrane Antigens) and Chad (Chimpanzee adenovirus) are just a few of the examples of the technology we use. Using SAM technology platform, for example, we can take part of the code of a virus and produce the messenger RNA molecule. Once injected in the body of the vaccinated patient, the cells of the recipient begin to produce the vaccine. It’s really the factory of the vaccine."
  • "Some new technologies can take years to develop; for more than 20 years we have been working on Adjuvant Systems, a technology that enhances the immune system’s response to a vaccine. This has made it possible to develop vaccines that target specific age groups, such as older people. As we age, so does our immune system, which means a vaccine may require the boosting effect of an adjuvant to help make it work more effectively."
  • "GSK and 23andMe today unveiled an exclusive four-year collaboration that will focus on research and development of innovative new medicines and potential cures, using human genetics as the basis for discovery. The collaboration will combine 23andMe’s large-scale genetic resources and advanced data science skills, with the scientific and medical knowledge and commercialisation expertise of GSK. The goal of the collaboration is to gather insights and discover novel drug targets driving disease progression and develop therapies for serious unmet medical needs based on those discoveries."
  • "Together, GSK and 23andMe will focus on translating genetic and phenotypic data into R&D activities that will:"
  • "• Improve target selection to allow safer, more effective ‘precision’ medicines to be discovered. Genetic data can significantly improve our understanding of diseases, their pathways and mechanisms, supporting the design and development of more targeted medicines. Use of genetic data in selecting drug targets can increase both the probability of success in a particular indication and avoid unwanted safety risks."
  • "• Support identification of patient subgroups that are more likely to respond to targeted treatments. Scale is critical for the detection of genetic effects in smaller subsets of diseases and patients. With over 80% of 23andMe’s customer base consenting to participate in research, their aggregate and de-identified data could help enable the discovery of a significant number of novel associations from a diverse range of people, which would not otherwise be possible."
  • "• Allow more effective identification and recruitment of patients for clinical studies.The ability to identify and invite patients with a particular disease, and in some case specific genetic subgroups, to participate in studies that are relevant to them could significantly shorten recruitment and reduce clinical development timelines, allowing medicines to be delivered to patients more efficiently."
  • "23andMe uses genotyping analysis, which is the process for determining which genetic variants an individual possesses. DNA can be extracted from mouth cells in a small saliva sample, and then processed on a special silicon chip that is capable of reading hundreds of thousands of variants in your genome. The genome is much like an owner’s manual for your body. It contains the genetic instructions needed to build and operate the body."
  • "This information will help us to quickly and accurately identify new drug targets and approaches to treat diseases such as cancer, Parkinson’s, inflammatory diseases and more."
  • "An HIV treatment made up of two drugs, rather than the usual three, has been approved by the US Food and Drug Administration, potentially handing GlaxoSmithKline a significant boost in its battle for market share with American biotech Gilead Sciences. GSK’s new medicine, Dovato, will be the first single-tablet, two-drug regimen sanctioned for adults who have not previously been treated for the disease. Made up of two medicines, dolutegravir and lamivudine, it follows a series of clinical trials that have demonstrated two drugs are as effective as three at suppressing the virus, achieving the same result but with less toxicity. "
  • "Gilead currently dominates the overall HIV market, worth around $28bn, with around 53 per cent share compared with only about 22 per cent for GSK. Deborah Waterhouse, chief executive of ViiV Healthcare, a specialist HIV company majority-owned by GSK, argued that the UK drugmaker could assert dominance over its rival through the success of dolutegravir"
  • "“That’s where we believe we can take leadership over time and at the core of that is the two-drug regimen,” she added."
  • "(Reuters) - British drugmaker GlaxoSmithKline Plc said on Thursday that its three-in-one drug Trelegy met the main goal of a late-stage asthma study, signalling a possible boost to its lung medicines division that has been hit by generic competition."
  • "The company, along with co-developer Innoviva Inc, said the once-daily inhaler improved lung function in patients with uncontrolled asthma, compared to its other medicine Relvar/Breo Ellipta."
  • "However, GSK said Trelegy Ellipta did not meet its secondary goal of showing a reduction in the rate of exacerbations."
  • "“We plan to submit these data for regulatory review after the full dataset is available,” said GSK’s Chief Scientific Officer Hal Barron."
  • "The drug became the first once-daily triple medicine for COPD when U.S. regulators gave it the green light in late 2017, putting GSK ahead of rivals such as AstraZeneca and Novartis."
  • "GlaxoSmithKline plc today announced that TESARO, an oncology-focused business acquired by GSK, submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for ZEJULA (niraparib). The application was granted priority review and has an action date of 24 October 2019."
  • "The sNDA supports a potential new indication for the treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer patients who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with either: • BRCA mutation or • Homologous recombination deficiency (HRD) and have progressed more than six months after the last platinum-based chemotherapy."
  • "Mary Lynne Hedley, Ph.D., President and Chief Operating Officer of TESARO, said, “The results of the QUADRA study demonstrate that ZEJULA is active as a late-line treatment for patients beyond those with BRCA mutations. With this study, we continue to advance our mission to provide more patients with ovarian cancer an opportunity to benefit from treatment with ZEJULA.”"
  • "GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinjector and a pre-filled safety syringe, for patients or caregivers to administer once every four weeks, after a healthcare professional decides it is appropriate. This is the first anti-IL5 biologic to be licensed in the US for at-home administration, and the first respiratory biologic to be approved for administration via an autoinjector."
  • "This approval will give healthcare professionals and people living with severe eosinophilic asthma (SEA) or the rare disease eosinophilic granulomatosis with polyangiitis (EGPA) the option for Nucala to be administered outside of a clinical setting by a patient or caregiver after their healthcare professional agrees this approach is appropriate. The original lyophilised powder version remains available for administration by a healthcare professional. "
  • "Dr. Hal Barron, Chief Scientific Officer and President, R&D, GSK, said: “Nucala’s efficacy is well-established and this approval means that, for the first time, we are able to provide patients living with these debilitating conditions the option of receiving this important medicine in their own home.”"
  • "GSK announces approval of Shingrix in China for prevention of shingles in adults aged 50 and over"
  • "GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the National Medical Products Administration (NMPA) has approved Shingrix for the prevention of shingles (herpes zoster) in adults aged 50 years or older. Shingrix is a recombinant subunit adjuvanted vaccine given intramuscularly in two doses."
  • "The approval is in response to last year’s inclusion of Shingrix on a list of 48 ‘clinically urgently needed new medicines’ in China designated for expedited review, reflecting the country’s prioritization of critical new prevention and treatment options."
  • "Dr. Thomas Breuer, Senior Vice President and Chief Medical Officer of GSK Vaccines said: “Today’s approval of Shingrix in China is recognition of the significant scientific advance this vaccine represents. In the pivotal studies the vaccine has shown over 90% efficacy across all age groups in the prevention of shingles, a disease that affects one in three people across the Asia-Pacific region[iii]. It can result in lasting pain and other complications which can severely impact the quality of people’s lives.”"
  • "Introduction of the vaccine into China will be phased, starting in 2020, to ensure consistent and reliable supply of the vaccine to all countries in which the vaccine has been launched. Over the next several years, GSK expects to increase supply of Shingrix globally and is investing in significant capacity expansion."
  • "GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced headline results from the pivotal phase III CAPTAIN study of once-daily single inhaler triple therapy Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol: FF/UMEC/VI) compared to Relvar/Breo Ellipta (FF/VI), in the treatment of patients living with uncontrolled asthma."
  • "The study met its primary endpoint, demonstrating a statistically significant 110mL improvement in lung function (measured by change from baseline in trough FEV1 at 24 weeks of treatment) for FF/UMEC/VI 100/62.5/25mcg (p<0.001, 95% CI: 66-153 mL) compared with Relvar/Breo 100/25mcg and a statistically significant 92mL improvement in trough FEV1for FF/UMEC/VI 200/62.5/25mcg versus Relvar/Breo 200/25mcg (p<0.001, 95% CI: 49-135 mL)."
  • "Dr. Hal Barron, Chief Scientific Officer and President, R&D, GSK, said: “We believe a once-daily single inhaler triple therapy that improves lung function is an advance for patients with uncontrolled asthma since this option is not currently available. We plan to submit these data for regulatory review after the full dataset is available.”"
  • "ViiV Healthcare submits New Drug Application to US FDA for the first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine for treatment of HIV"
  • "If approved, cabotegravir and rilpivirine would be the first-ever long-acting, injectable treatment regimen for adults living with HIV."
  • "ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for the investigational, monthly, injectable, two-drug regimen of ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine to treat HIV-1 infection in adults whose viral load is suppressed and who are not resistant to cabotegravir or rilpivirine."
  • "The submission is based on the global ATLAS (Antiretroviral Therapy as Long-Acting Suppression) and FLAIR (First Long-Acting Injectable Regimen) pivotal phase III studies that included more than 1,100 patients from 16 countries and demonstrated the combination of cabotegravir and rilpivirine, injected monthly, was as effective as a standard of care, daily, oral, three-drug regimen in maintaining viral suppression throughout the 48-week study period. These results were presented in March at the 2019 Conference on Retroviruses and Opportunistic Infections."
  • "Deborah Waterhouse, CEO of ViiV Healthcare, said: “The long-acting, once-monthly, injectable regimen of cabotegravir and rilpivirine has the potential to give people living with HIV one month between doses with similar safety and efficacy as today’s standard of care – an oral three-drug regimen that has to be taken every day. ViiV Healthcare is proud to be at the forefront of this innovation in HIV treatment and we look forward to working with the FDA to provide people living with HIV in the US this novel option.”"
  • "GlaxoSmithKline (GSK) is a global pharmaceutical and consumer health productscompany and is headquartered in Brentford, the UK. The company operates in more than 100 countries and has a strong presence in US, Europe and Asia-Pacific. GSK is looking forward to expanding its product portfolio and is investing heavily on Research and development for the same."
  • "Strong R&D boosts portfolio expansion: GSK has made focused efforts towards developing a strong research and development wing. The company has made progress in respiratory, HIV and cardiovascular medicines to name a few. GSK’s commitment to technologically driven R&D innovation helps the company to strengthen its market position."
  • "Strong Sales and Distribution network: GSK has established a strong sales and distribution network in India as well as across the globe. A strong distribution network ensures availability of its products everywhere and enhances its ability to provide its newer products to the customer as soon as possible."
  • "GSK-Novartis JV: Novartis announced a consumer healthcare and vaccines joint venture in in 2015 in, which benefits both the Pharmaceutical giants to increase penetration, introduce new products and enhance market share."
  • "Healthcare fraud allegations affect brand image: GSK has been alleged, in some countries, to have unlawfully promoted prescription drugs, false pricing charges, and failure to report safety data. For instance, charges of promoting antidepressants in the US which were not approved by FDA. Such instances affect brand image of the company."
  • "Below are the top 10 GlaxoSmithKline Pharmaceuticals Ltd competitors: 1. Abbott Laboratories 2. Amgen 3. AstraZeneca 4. Bristol Myers Squibb 5. Johnson & Johnson 6. Merck 7. Novartis 8. Pfizer 9. Roche Holdings 10. Sun Pharma Industries "
  • "The pharma giant remains on top as rivals Hikma, Gilead and Mylan suffer setbacks"
  • "Pharmaceuticals giant GlaxoSmithKline (GSK) is emerging stronger after surviving competitive threats against its asthma and HIV treatments from rivals Hikma (HIK), Gilead Sciences and Mylan."
  • "Several companies have been attempting to develop a generic version of GlaxoSmithKline’s off-patent asthma medicine Advair Diskus – and all have failed to gain the necessary regulatory approval so far."
  • "Earlier this year, the US Food and Drug Administration blocked the launch of Mylan’s Wixela Inhub in its current form and delayed the launch of Hikma’s VR315."
  • "GlaxoSmithKline also faces competition from Gilead’s HIV treatment Bictegravir, but the latest clinical studies revealed it was only equally as good, rather than superior. This is important as the HIV division has been one of the biggest growth drivers for Glaxo over recent years."
  • "Beaufort Securities analyst Ben Maitland says these developments highlight the strength of company’s drug portfolio and intellectual property, which makes it harder for its rivals to make superior products."
  • "EMPLOYEES99,817 • ASSETS (MIL USD)74,196 • SALES (MIL USD)39,382.71 • NET INCOME GROWTH123.98%"
  • "GSK recognizes that access to medicines and healthcare should be available to everyone who needs them, no matter where they live or how much they can afford. In many countries, we still need to improve access to essential existing antibiotics. We also need to ensure access to new antibiotics once they are launched. However, considering the growing threat of resistance, access should be combined with appropriate use of current and future antibiotic products, as well as improved access to vaccines and infection control, to reduce society’s dependence on antibiotics."
  • "Initiative’s objective GSK wants to ensure affordable access to new and existing antibiotics to the patients who need them, no matter where they live or how much they can afford. GSK also encourages appropriate use of these antibiotics. It is also committed to ensuring access to vaccines, which reduce infections that are often treated with antibioitics. "
  • "Initiative’s description To support access to existing GSK antibiotics, GSK applies tiered pricing based on a country’s wealth and ability to pay, capping the prices of medicines in Least Developed Countries (LDCs) at no more than 25% of prices charged in developed countries (see case study). "
  • "For new products, GSK has expanded a graduated approach to patents and intellectual property (IP) to widen access to medicines in the world’s poorest countries. GSK does not file for patent protection in Least Developed and Low Income Countries and we will seek to grant licences to generic manufacturers to supply versions of GSK antibiotics in Lower Middle Income Countries."
  • "To improve access to vaccines, GSK partners with Gavi, which funds immunisation programmes for some of the world’s poorest countries. Gavi-eligible countries always get our lowest prices, which can be as little as one-tenth of those for developed nations. GSK has committed to freeze vaccine prices for graduating countries for ten years. GSK will provide Gavi with more than 850 million vaccine doses at reduced prices to help protect 300 million children in the developing world by 2024."
  • "It re-invests 20% of profits made in LDCs back into improving the healthcare infrastructure and educating communities in those countries to recognise diseases and refer to health services; since 2009 GSK has invested in 35 LDCs, helping support the training of 40,000 frontline health workers and reaching 11 million people. GSK also invests in Personal Hygiene and Sanitation Education (PHASE) for children in the world’s poorest countries and, through partnership with Save the Children, it has developed an antiseptic gel to prevent umbilical cord infections in newborn infants."
  • "GSK Consumer Healthcare’s three areas of focus 1. Consumer expectation More and more people are searching for healthcare solutions. 160bn annual health-related searches was the figure cited by Kristensen. And while she admits that “not all of those [searches] are credible sources of information”, the company has to ask “how do we organise ourselves for this? What content do we need?” "
  • "2. Consumer journey Half of sector growth over the next five years will come from ecommerce, according to Kristensen, who says that the consumer increasingly “does not distinguish between online and off-… with 75% of us comparing products on our phones in store.” As GSK Consumer Healthcare is multidistribution and not direct-to-consumer, the challenge according to Kristensen is “to work with customers and retailers to make sure we are there for moments that matter.” "
  • "3. Data Kristensen believes the data revolution will have a “positive and long-lasting impact on people’s health” and she gave one example of how data is influencing marketing and commerce. "
  • "Last year, GSK and its brand Theraflu created a cold and flu tracker for the Russian market. The tracker used search, social and weather data to identify instances of cold and flu across each region in Russia. This tool involved content, subject matter experts and product information offered up to the user, and provided the brand with first-party data to enable better targeting of media. Kristensen stated that the tracker tool was much more powerful than the Theraflu brand website had proven previously."
  • "Owning the tech stack In 2017, GSK partnered with Google to bring data management in-house. Kristensen said this made the company the first consumer healthcare brand to own its full tech stack. Combined with a framework of KPIs, Kristensen adds that this tech stack is vital to “creating assets at scale” and “buying digital media much more effectively.” "
  • "Digital innovation hub & new processes The healthcare brand now has a digital innovation hub which is global and ensures “proper processes are embedded in the business.” A digital advisory board holds the activities of the hub to account, offering an external and guiding voice. "
  • "Priorities 1. Upgrade media ROI GSK is driving financial efficiency from digital media using a holistic approach. “We have some TV-dominated markets,” say Kristensen, “but it doesn’t mean people aren’t online. So we review the media mix and we’re conscious digital can’t be the first thing we cut when we’re under pressure. “We have a robust media mix model.” "
  • "2. Boost ecommerce with omnichannel tactics “We’ve had to nail the basics… But they are anything but basic in a big FMCG. We have had to reset [our business] to work with algorithms when we are working with pureplays and bricks and clicks.” "
  • "3. Efficient content “We can’t just repurpose TV creative… We now have a global digital asset management tool which means smaller markets can take assets and run with them.” "
  • ". Spark disruption “Our mantra is do and learn. Not test and learn, which implies we can’t do it. We try on the job in small sprints.” Initiatives such as shark tank funds – panels that approve new project teams –are “fuelling creative spirit internally.” "
  • "The FCP ecommerce model GSK Consumer Healthcare has created the ‘FCP model’, which stands for ‘findability, conversion, performance’. Kristensen gave some excellent examples of work on each of these fronts, which she said was an effort designed to look good in all channels – in her words “are we happy spending huge amounts on packaging but then look horrendous in the Amazon channel? No.” "
  • "Why is diversity, and specifically the advancement of women, so important to your organisation? Creating a diverse and inclusive organisation is an important element of our key priorities of Innovation, Performance and Trust and central to being a modern employer. We believe that diversity brings improved performance and creativity and helps better reflect our shopper and consumer base. Although we have an almost 50/50 gender split of employees in GSK Consumer Healthcare in Europe, we would like to see more senior roles filled by women."
  • "Which diversity initiatives do you have in your organisation? Women made up half of our new graduates and participants of our Esprit programme* in 2017, and 38% of our new apprentices in science, technology and engineering roles, where women have traditionally been underrepresented. Additionally, our Women’s Leadership Initiative Employee Resource Group now has more than 4,000 employee members in more than 70 countries. We provide coaching and support for high-performing female managers through our Accelerating Difference programme, which incorporates individual and group coaching, as well as sponsorship by senior managers, and which also actively engages men in dialogue about gender diversity and inclusion."
  • "What role does LEAD play in reaching your organisation’s diversity goals? We want to be an organisation which develops female leaders, supports them on the journey, and enables them to have successful careers. By being a partner, we support the LEAD Network. This partnership offers a lot of opportunities to GSK. The LEAD Network will share the know-how and support us in creating a diversity strategy which is specific to GSK Consumer Healthcare in Europe. We will have access to best practice from leading companies in the industry to understand how they advance women to transform their businesses."
  • "GSK employees will have access to fantastic speaker opportunities, mentorship programmes, networking opportunities, access to webinars, and much more. In addition, the Network will help develop female talent through mentoring relationships between senior executives in consumer goods and retail sectors in Europe which will be invaluable to them."
  • "GlaxoSmithKline, Teva, Takeda Investing in Global Sustainability Performance with the Responsible Health Initiative"
  • "Three leading health and pharmaceutical companies -- GlaxoSmithKline, Teva, Takeda – and EcoVadis , the leading provider of sustainability risk and performance ratings for global supply chains, today announced the launch of the Responsible Health Initiative. The mission of the new sector initiative is to use collaboration and technology to improve the visibility, efficiency and sustainability impact of the global health supply chain."
  • "“As business models across the health and pharmaceutical industries continue to evolve and overlap, it makes sense for organizations to focus on shared needs, goals and opportunities in sustainability, and act on them through the collective industry supply chain,” said Pierre-Francois Thaler, Co-CEO and Co-Founder of EcoVadis. “Peer collaboration is a proven model for enabling companies in any sector to easily harmonize sustainability performance measurement and extend visibility. We are confident the Responsible Health Initiative will help create the networked impact the healthcare industry needs.”"
  • "The shared vision for the Responsible Health Initiative includes: • Harmonizing industry standards for online CSR assessments, with reliable indicators and global benchmarks • Adopting a common platform to ease sharing of CSR performance among suppliers/third parties and RHI members • Implementing shared tools to boost supplier engagement and improvement plans • Working together to reduce risk and increase visibility in the supply chain "
  • "Following the completion of the deal, the UK-based company now focuses on its three core businesses – Pharmaceuticals (respiratory, HIV), Vaccines (pediatric, adolescent, adult, and travel vaccines) and Consumer Healthcare (wellness, oral health, nutrition and skin health products). However, Glaxo is currently focusing on adding cancer drugs to boost its pharma pipeline."
  • "Meanwhile, like many of its peers, Glaxo is facing challenges in the form of stiff competition, genericization, pricing pressure and slowing growth in emerging markets. In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential, restructuring and cost-cutting initiatives and performance of new products apart from the usual top-and bottom-line numbers."
  • "A five-year partnership focused on strengthening local health systems. We are working together with communities to support their efforts to fight malaria"
  • "Over the past 15 years, significant progress has been made against malaria. The WHO World Malaria Reportshows that deaths have more than halved since 2000, but it also shows that after an unprecedented period of success in global malaria control, progress has stalled and can be easily reversed, not in a few years, but during the next rainy season."
  • "Malaria continues to claim nearly half a million lives every year, most of them very young children in Africa. This preventable and treatable disease continues to take a heavy human and economic toll."
  • "Together with Comic Relief, we aim to make a real difference to those living in five malaria endemic countries. Comic Relief and GSK believe that one of the best ways to fight malaria is to work with communities to help strengthen local and national health services and improve their ability to combat the disease."
  • "Both GSK and Comic Relief believe that defeating malaria will unlock human and economic potential. it will give children a chance to grow up healthy, and health workers the chance to focus their resources on other challenges. A malaria free future is worth fighting for."
  • "How we’re working with Save the Children to save one million children’s lives Every day 15,000 children under the age of five die - most from preventable causes. We’re working together with Save the Children to change that. "
  • "Our pioneering and powerful partnership with Save the Children has now been extended to 2022. We continue to work together combining GSK’s scientific and manufacturing expertise with Save the Children’s on-the-ground experience to find new ways to help bring down the number of children dying from preventable and treatable diseases."
  • "In 2013 we embarked on an ambitious global partnership with Save the Children that is combining the two organisations’ global expertise, skills and energy to tackle the ambitious goal of helping to save one million children’s lives. Together we are finding new ways to help reduce child mortality."
  • "Specifically, the GSK and Save the Children partnership focuses on: • improving access to basic healthcare – prevention and treatment – where the need is greatest • training and equipping health workers in the poorest communities • developing child-friendly medicines • working at local and global levels to call for stronger child health policies"
  • "Since launching our partnership, we have reached over 2.8 million children in 45 countries. Over 97,000 children under-five have been fully immunised and over 187,800 children have been treated for diarrhoea, malaria or pneumonia."
  • "With GSK Consumer Healthcare’s heritage in specialist oral health, we know the importance of a healthy mouth, which is why we’re proud to launch a new partnership with Smile Train, a world-leading charity which empowers local medical professionals to provide free, life-changing surgery and comprehensive cleft care to children with cleft lip and palate in more than 85 countries."
  • "Together with Smile Train, we are united in our shared vision and commitment to help transform lives, one smile at a time."
  • "Over the next 5 years, we will provide Smile Train with valuable funding, support and expertise to help more children living with clefts lead full and productive lives, as well as helping increase awareness and education about cleft."
  • "• Smile Train provide 100% free comprehensive care for cleft patients. This can range from a nutritional programme to ensure the child is physically fit for surgery (since many cleft patients will be malnourished) to orthodontic care and speech therapy post-surgery where available."
  • "This year, GSK deepened its commitment to our U.S. preparedness work with a three-year investment aimed at maximizing the impact of our critical work; including helping to mobilize rapid responses to help children affected by natural disasters, strengthen the capacity of staff and volunteers and increase our efficiency through data system improvements."
  • "The global GSK employee workforce of over 100,000 are encouraged to support the partnership through award-winning Orange United fundraising campaigns, as well as by contributing their time and expertise through GSK’s skill-based PULSE volunteer engagements. So far, over 100 GSK employees have been placed in Save the Children roles, drawing on their professional expertise to provide valuable skilled services."
  • "Abbott Laboratories WORLDWIDE SALES $30.6B ORGANIC SALES GROWTH1 7.3% "
  • "• Increases Fourth Quarter Revenues 10% to $6.0 Billion, 9% for Full Year to $22.6 Billion"